---
schema_version: "secwatch.filing_event.v1"
accession: "0001802768-23-000022"
form_type: "8-K"
ticker: "RPRX"
cik: "0001802768"
company_name: "Royalty Pharma plc"
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T02:33:31.540463+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Royalty Pharma Q2 adj cash receipts $545M (+4%); raises 2023 guidance to $2.9-2.975B

## Summary
- Net cash from ops $608M (+6% YoY); Adjusted Cash Receipts $545M (+4%), Adjusted EBITDA $498M (+4%).
- Raised 2023 Adj Cash Receipts guidance to $2.900B-$2.975B from $2.85B-$2.95B, excluding new transactions.
- YTD announced transactions up to $1.7B, including $659M upfront; began share repurchases.
- CF franchise royalties +13% to $206M; Trelegy added $37M, Spinraza $13M; Imbruvica -22%, Xtandi -22%.
- Adjusted Cash Flow $512M (+6%) driven by EBITDA growth and higher net interest received.

## SEC filing metadata
- accession: 0001802768-23-000022
- form_type: 8-K
- ticker: RPRX
- cik: 0001802768
- company_name: Royalty Pharma plc
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802768/000180276823000022/0001802768-23-000022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802768/000180276823000022/rprx-20230808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001802768-23-000022
- JSON: https://secwatch.observer/filing/0001802768-23-000022.json
- Plain text: https://secwatch.observer/filing/0001802768-23-000022.txt

## Key facts
- Earnings Releases
  Royalty Pharma plc updated its the quarter ended June 30, 2023 guidance (raised).
  - Period: the quarter ended June 30, 2023
  - Guidance: raised
  - Result: reported results
  source text: Royalty Pharma plc issued a press release announcing its financial results for the quarter ended June 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1802768/000180276823000022/0001802768-23-000022-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.